David J. Parker

David, who has more than 20 years of private equity experience, joined Ampersand in 1994. During 2007, David joined Victory Pharma, an Ampersand portfolio company, as EVP and CFO, before returning in 2010 as a General Partner to Ampersand. David is based in our Amsterdam office. David’s current and past board seats include Avista, Bako, Bioventus, GenDx, Gyros PTI, NOVEX, Roadrunner and Signature Genomics. Prior to joining Ampersand, David spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and a M.B.A. from Wharton.